At o2h discovery, we follow a streamlined process for hit-to-lead development encompassing rational design for confirming structure-activity relationship (SAR) of short-listed hit series with the synthesis and evaluation in biological assays and early ADMET studies. We can support in accelerating your design-make-test-analyse cycles providing a robust iterative screening platform to advance your discovery program.
Feel free to reach out for a conversation on ways to expedite your drug discovery project with our highly qualified scientists who can develop customizable assays for diverse target classes, functional assays and selectivity profiling of shortlisted hits. We have a wide range of in- vitro ADME assays and capabilities for pharmacokinetic profiling of short listed compounds. Using structure-guided approach we can focus on synthetic strategies ultimately leading to the selection of the most promising compounds for further development.
To know more about our integrated drug discovery services offering or to request our brochure, please reach out to us at discovery@o2h.com.
